Evidence map›Paper›PMID 20177670›Full record

ArticleThe Journal of membrane biology2010

Cloning and functional expression of an MscL ortholog from Rhizobium etli: characterization of a mechanosensitive channel.

Daniel Balleza, Froylan Gómez-Lagunas, Carmen Quinto

Abstract read
PubMed Publisher
In one paragraph

Article in The Journal of membrane biology, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.8field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 7 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 2 institutions in 3 countries.

Daniel BallezaLaboratory of Molecular Biology, University of Wisconsin, Madison, WI, 53706, USA. dballeza.uwisc@gmail.com
Froylan Gómez-Lagunas
Carmen Quinto
Universidad Nacional Autónoma de México · MXUniversity of the Basque Country · ES

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Rhizobium etli is equipped with several systems to handle both hyper- and hypo-osmotic stress. For adaptation to hypo-osmotic stress, R. etli possesses a single gene with clear homology to MscS, four MscS-like channels and one ortholog of MscL (ReMscL, identity approximately 44% compared to Escherichia coli MscL). We subcloned and expressed the ReMscL channel ortholog from R. etli in E. coli to examine its activity by patch clamp in giant spheroplasts and characterized it at the single-channel level. We obtained evidence that ReMscL prevents the lysis of E. coli null mutant log-phase cells upon a rapid, osmotic downshock and identified a slight pH dependence for ReMscL activation. Here, we describe the facilitation of ReMscL activation by arachidonic acid (AA) and a reversible inhibitory effect of Gd(3+). The results obtained in these experiments suggest a stabilizing effect of micromolar AA and traces of Gd(3+) ions in the partially expanded conformation of the protein. Finally, we discuss a possible correlation between the number of gene paralogs for MS channels and the habitats of several microorganisms. Taken together, our data show that ReMscL may play an important role in free-living rhizobacteria during hypo-osmotic shock in the rhizosphere.

Indexed as

Mechanotransduction, CellularAmino Acid SequenceArachidonic AcidBacterial ProteinsCloning, MolecularEscherichia coliEscherichia coli ProteinsGadoliniumIon Channel GatingIon ChannelsMolecular Sequence DataOsmotic PressurePatch-Clamp TechniquesRhizobium etliSequence AlignmentArachidonic AcidBacterial ProteinsEscherichia coli ProteinsGadoliniumIon ChannelsMscL protein, E coli

Identifiers

PMID20177670
OpenAlexW2093389523

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.